Please login to the form below
Ligelizumab
This page shows the latest Ligelizumab news and features for those working in and with pharma, biotech and healthcare.
FDA approves new self-injection administration for Xolair
According to Novartis, ligelizumab binds to IgE with an 88-fold higher affinity than Xolair, with the two binding differently to the antibody. ... Novartis picked up ligelizumab following its acquisition of UK firm Ziarco in 2016.
Latest news
-
Novartis reveals positive efficacy data for Xolair follow-up
Novartis picked up ligelizumab following its acquisition of UK firm Ziarco in 2016. ... If all goes to plan, Novartis is set to file ligelizumab by the end of 2021.
-
Novartis highlights emerging assets and late-stage pipeline at R&D day
Ligelizumab (QGE031), a new treatment for chronic spontaneous urticaria, which has phase 3 results and is due to be filed with regulators by the end of 2021.
-
Novartis adds oral eczema drug with Ziarco acquisition
fevipiprant (QAW039) in phase II and ligelizumab (QGE031) for CIU.
Novartis reveals positive efficacy data for Xolair follow-up
Novartis highlights emerging assets and late-stage pipeline at R&D day
Novartis adds oral eczema drug with Ziarco acquisition
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital account director
-
Competitive
-
Events Executive
-
Depending on Experience
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Understanding the ‘real world’ starts and ends with the patient
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Sanofi raises profit forecast following positive Q2 results
- Biogen/Eisai push for second approval in Alzheimer’s disease
- Reducing primary care antibiotic use may not be enough to counter antimicrobial resistance
- SoftBank buys $5bn stake in Roche
- Live Webinar: Making Wearable Technology Scalable and Adoptable
- Live Webinar: Transforming the Future of Health & Aging from a Global Health & Social Impact Approach
- Investors respond positively to “strong” Eli Lilly results
- Amanda Pritchard becomes NHS England’s first female chief executive
- Biogen/Eisai push for second approval in Alzheimer’s disease
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- Ask the writers: Transitioning from academia to medical writing
- Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
- Strategic launch planning: familiar framework, new mindset
- By James Aird...
- Guide
- How to embrace behavioural science principles in healthcare MR...
